CAJ | 학술논문

目的探讨奈达铂联合甲地孕酮同步放化疗治疗中晚期宫颈癌的近期疗效.方法 42例中晚期(Ⅱb～Ⅳa期)宫颈癌患者随机分为单纯放疗组(RT组,21例),奈达铂联合甲地孕酮同步放疗组(RT+C组,21例),两组放疗方法相同.RT+C组在放疗开始后,每周1次奈达铂30 mg/m2,静脉滴注,第1天,共4～5周,并常规给予止吐药物及适当水化,患者从治疗开始均每天服用甲地孕酮160mg至治疗结束.结果 RT+C组患者中,完全缓解(CR)17例(81.0%),部分缓解(PR)4例(19.0%),有效率为100%;RT组患者中,CR 8例(38.1%),PR 9例(42.9%),有效率81.0%.RT+C组的CR及有效率均高于RT组,差异有统计学意义.RT+C组患者的1年生存率为100%(21/21),RT组患者的1年生存率为81.0%(17/21),差异有统计学意义(x2=4.42,P＜0.05).结论奈达铂联合甲地孕酮同步放化疗可提高中晚期宫颈癌的近期疗效,虽毒性反应有所增加,但患者可以耐受.
목적 탐토내체박연합갑지잉동동보방화료치료중만기궁경암적근기료효.방법 42례중만기(Ⅱb～Ⅳa기)궁경암환자수궤분위단순방료조(RT조,21례),내체박연합갑지잉동동보방료조(RT+C조,21례),량조방료방법상동.RT+C조재방료개시후,매주1차내체박30 mg/m2,정맥적주,제1천,공4～5주,병상규급여지토약물급괄당수화,환자종치료개시균매천복용갑지잉동160mg지치료결속.결과 RT+C조환자중,완전완해(CR)17례(81.0%),부분완해(PR)4례(19.0%),유효솔위100%;RT조환자중,CR 8례(38.1%),PR 9례(42.9%),유효솔81.0%.RT+C조적CR급유효솔균고우RT조,차이유통계학의의.RT+C조환자적1년생존솔위100%(21/21),RT조환자적1년생존솔위81.0%(17/21),차이유통계학의의(x2=4.42,P＜0.05).결론 내체박연합갑지잉동동보방화료가제고중만기궁경암적근기료효,수독성반응유소증가,단환자가이내수.
Objective To investigate the early efficacy of nedaplatin combined with megestrol in concurrent chemoradiotherapy for advanced cervical cancer. Methods Forty-two cases of cervical cancer (FIGO Ⅱb to Ⅳa) were divided randomly into two groups: radiotherapy alone (21 cases) and radiation plus chemotherapy (Nedaplatin) group. The same radiotherapy was given to the two groups. Patients of the RT + C group received nedaplatin 30 mg/m2 in intravenous drip infusion once weekly on day 1, for 4 to 5 weeks, and megestrol 160 mg orally every day during the radiation therapy. Results The early outcome:the complete remission rate was 81.0% and partial remission rate was 19.0% in the RT + C group,significantly better than the CR (38.1%) and PR (42.9%) in the RT group. The 1-year survival rates in the two groups were 100% (21/21) and 81.0% ( 17/21 ), respectively, with a significant difference between the two groups ( P ＜ 0.05 ). Conclusions The combination of nedaplatin and megestrol with concurrent chemoradiotherapy can improve the early outcome of advanced cervical cancer, with somewhat increased but tolerable adverse effects.